The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?

Abstract

Get full access to this article

View all access options for this article.

References

Cannon

Blazing

Giugliano

. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

Robinson

Farnier

Krempf

. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–1499.

Sabatine

Giugliano

Wiviott

. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–1509.

Baigent

Keech

Kearney

. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.

Voight

Peloso

Orho-Melander

. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 2012; 380: 572–580.

Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014; 371: 2072–2082.

Swerdlow

Preiss

Kuchenbaecker

. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351–361.